Investor alert: law offices of howard g. smith announces investigation of chembio diagnostics, inc. (cemi) on behalf of investors

Bensalem, pa.--(business wire)--law offices of howard g. smith announces an investigation on behalf of chembio diagnostics, inc. ("chembio" or the "company") (nasdaq: cemi) investors concerning the company and its officers’ possible violations of federal securities laws. in april 2020, the company’s covid-19 antibody test was one of the first to be granted emergency use authorization (“eua”) by the u.s. food and drug administration (“fda”). then, on june 17, 2020, before the market opened, the fda revoked the eua for chembio’s dual path platform covid-19 serology test due to concerns regarding the test’s accuracy. specifically, the fda found that the “benefits no longer outweigh its risks” and that “it is not reasonable to believe that the test may be effective” because it “generates a higher than expected rate of false results and higher than that reflected in the authorized labeling for the device.” on this news, the company’s share price fell $6.04, or nearly 60%, to close at $3.89 per share on june 17, 2020. if you purchased chembio securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact howard g. smith, esquire, of law offices of howard g. smith, 3070 bristol pike, suite 112, bensalem, pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com. this press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules.
CEMI Ratings Summary
CEMI Quant Ranking